Drugs / Rhu-pGSN
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05789745 | Mar → May 2023 | — | BioAegis Therapeutics Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05947955 | Oct 2024 → Oct 2026 expected | acute respiratory distress syndrome, infectious disease | BioAegis Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhu-pGSN | “Study BTI-101 is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation, parallel design study to evaluate the safety, tolerability, and pharmacokinetics of...” NCT05789745 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Plasma Gelsolin” NCT05789745 ↗ |
| Route | Intravenous | “intravenous administration of either 6, 12, 18, or 24 mg/kg at time 0, 12, 36, 60 and 84 hours” NCT05789745 ↗ |